AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2878600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 150 mg twice daily
Number of subjects: 40
Study 2878600 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 40
Study 29210007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy (n=179)
Number of subjects: 358
Study 29210007 — intervention group
Group type: COMPARATOR
Intervention: Unilateral varicocelectomy (n=179)
Number of subjects: 358
Study 29210007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy
Number of subjects: 358
Study 29210007 — intervention group
Group type: COMPARATOR
Intervention: Unilateral varicocelectomy
Number of subjects: 358
Study 28139557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg twice daily
Number of subjects: 107
Study 28139557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg twice daily
Number of subjects: 107
Study 28139557 — intervention group
Group type: COMPARATOR
Intervention: Combination of bisoprolol 1.25‐2.5 mg once daily and ivabradine 2.5‐7.5 mg twice daily
Number of subjects: 107
Study 25762833 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic glue (group A)
Number of subjects: 89
Study 25762833 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular sutures (group B)
Number of subjects: 89
Study 22212127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix(®))
Number of subjects: 1104
Study 20159247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast 7 mg
Number of subjects: 583
Study 20159247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 17627746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 229
Study 17627746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 16278987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine-free essential amino acid tablets (AA tablets)
Number of subjects: 19
Study 16278987 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 19
Study 12385350 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated ribbon gauze
Number of subjects: 94
Study 12385350 — intervention group
Group type: COMPARATOR
Intervention: Ear wick
Number of subjects: 94
Study 9951432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 7.5 mg hydrocodone bitartrate with 200 mg ibuprofen
Number of subjects: 0
Study 9951432 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone
Number of subjects: 0
Study 9951432 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 9951432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7790461 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 23
Study 7790461 — intervention group
Group type: COMPARATOR
Intervention: bismuth, metronidazole, and nitrofurantoin
Number of subjects: 23
Study 7790461 — intervention group
Group type: COMPARATOR
Intervention: bismuth-antibiotic
Number of subjects: 23
Study 2133751 — intervention group
Group type: EXPERIMENTAL
Intervention: S26 Low Birthweight
Number of subjects: 49
Study 2133751 — intervention group
Group type: COMPARATOR
Intervention: Enfalac Premature
Number of subjects: 49
Study 2133751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preterm infant formulas
Number of subjects: 49
Study 2133751 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm breast milk supplemented with preterm infant formula
Number of subjects: 49
Study 30607985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT)
Number of subjects: 2
Study 30607985 — intervention group
Group type: COMPARATOR
Intervention: Vestibular rehabilitation therapy (VRT) plus placebo
Number of subjects: 2
Study 28049549 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Get Fit for Active Living (GFAL)' program
Number of subjects: 176
Study 26576520 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow group
Number of subjects: 130
Study 26576520 — intervention group
Group type: COMPARATOR
Intervention: Low flow group
Number of subjects: 130
Study 23425194 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-hard toothbrushes
Number of subjects: 35
Study 23425194 — intervention group
Group type: COMPARATOR
Intervention: Soft toothbrushes
Number of subjects: 35
Study 21499862 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 451
Study 21499862 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 451
Study 19357317 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid-treated seedlings (Merit Forest)
Number of subjects: 19
Study 19357317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypermethrin-treated seedlings (Forester)
Number of subjects: 19
Study 19357317 — intervention group
Group type: COMPARATOR
Intervention: Untreated seedlings
Number of subjects: 19
Study 16368345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60
Study 16368345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15086356 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B(6) (5 mg of folic acid plus 250 mg of vitamin B(6) daily)
Number of subjects: 158
Study 15086356 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 158
Study 11228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0
Study 11228214 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study 9196141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy EF irradiation
Number of subjects: 257
Study 9196141 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy EF irradiation
Number of subjects: 257
Study 9196141 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy EF irradiation
Number of subjects: 257
Study 9196141 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy for bulky disease
Number of subjects: 257
Study 8389710 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 therapy
Number of subjects: 20
Study 8389710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3318711 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine 20 mg/kg/day
Number of subjects: 15
Study 3318711 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine plus prednisolone
Number of subjects: 15
Study 3318711 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 15
Study 30558143 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acids (BCAA, Arginine, Citrulline)
Number of subjects: 16
Study 26286756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear IOLs (AcrySof UV‐filtering IOL, SA60AT)
Number of subjects: 98
Study 26286756 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow IOLs (AcrySof Natural blue‐light‐attenuating and UV‐filtering IOL, SN60AT with IMPRUV(®) filter)
Number of subjects: 98
Study 26286756 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange‐tinted blue‐filtering IOLs (PC440Y Optech)
Number of subjects: 98
Study 24457184 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (CKD‐EPI‐Creat+CysC)
Number of subjects: 0
Study 24457184 — intervention group
Group type: COMPARATOR
Intervention: eGFR (MDRD)
Number of subjects: 0
Study 24457184 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (CKD‐EPI‐Creat+CysC) and eGFR (MDRD)
Number of subjects: 0
Study 24350695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear frequency compression (NLFC)
Number of subjects: 44
Study 24350695 — intervention group
Group type: COMPARATOR
Intervention: Conventional processing
Number of subjects: 44
Study 24350695 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFC
Number of subjects: 44
Study 20033904 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (EET) for 12 months, 3 hours a week
Number of subjects: 120
Study 20033904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 17923439 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week karate program
Number of subjects: 11
Study 16357522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (single or double dose, weekly for four weeks and monthly thereafter)
Number of subjects: 43
Study 16357522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (double dose)
Number of subjects: 43
Study 16357522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (good antibody response)
Number of subjects: 43
Study 16357522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (serum EGF decreased below 168 pg/ml)
Number of subjects: 43
Study 16357522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (overall treatment)
Number of subjects: 43
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administered before antibiotic therapy (Group I - 25 patients)
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administered concomitantly with antibiotics (Group II - 19 patients)
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administered after beginning antibiotic therapy (Group III - 14 patients)
Number of subjects: 81
Study 15273838 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (Group IV - 23 patients)
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of neurological alterations
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological evaluation using WPSSI and WISC tests
Number of subjects: 81
Study 15273838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of sequelae (neurological, auditory, and intellectual level)
Number of subjects: 81
Study 11743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/elastin substitute combined with autograft
Number of subjects: 86
Study 11743380 — intervention group
Group type: COMPARATOR
Intervention: Conventional split-thickness autograft
Number of subjects: 86
Study 9024949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal TRH
Number of subjects: 2
Study 9024949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TRH
Number of subjects: 2
Study 9024949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal TRH (readministered)
Number of subjects: 2
Study 8510087 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg daily for 16 weeks
Number of subjects: 139
Study 8510087 — intervention group
Group type: COMPARATOR
Intervention: Captopril or Hydrochlorothiazide monotherapy for 4 weeks
Number of subjects: 139
Study 2879981 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain by subcutaneous injection
Number of subjects: 100
Study 2879981 — intervention group
Group type: COMPARATOR
Intervention: Schwarz strain by subcutaneous injection
Number of subjects: 100
Study 2879981 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain by aerosol
Number of subjects: 100
Study 2879981 — intervention group
Group type: COMPARATOR
Intervention: Schwarz strain by aerosol
Number of subjects: 100
Study 31302339 — intervention group
Group type: COMPARATOR
Intervention: SPX-101 (20 to 240 mg single doses and 10 to 120 mg BID for 14 days)
Number of subjects: 69
Study 31302339 — intervention group
Group type: EXPERIMENTAL
Intervention: SPX-101 (10 mg-120 mg BID for 7 days)
Number of subjects: 69
Study 26988864 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 1.2% ATV gel
Number of subjects: 71
Study 26988864 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 71
Study 25610954 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of chocolate milk daily
Number of subjects: 0
Study 25610954 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 0
Study 23419544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 28
Study 23419544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21170659 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency SEMS placement as a bridge to surgery
Number of subjects: 60
Study 21170659 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 60
Study 19843656 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID for 10 days followed by 10 mg BID for 6 days
Number of subjects: 148
Study 19843656 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 15 mg BID for 10 days followed by 20 mg BID for 6 days
Number of subjects: 148
Study 19843656 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 375 mg BID for 16 days
Number of subjects: 148
Study 19843656 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 days
Number of subjects: 148
Study 17074351 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen supplementation
Number of subjects: 0
Study 14764210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric rectal distension
Number of subjects: 12
Study 14764210 — intervention group
Group type: COMPARATOR
Intervention: Sham distension
Number of subjects: 12
Study 11506110 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tube compensation during APRV
Number of subjects: 14
Study 11506110 — intervention group
Group type: COMPARATOR
Intervention: APRV without automatic tube compensation
Number of subjects: 14
Study 9491583 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary task incentive framed in terms of gains (promotion framed)
Number of subjects: 0
Study 9491583 — intervention group
Group type: COMPARATOR
Intervention: Monetary task incentive framed in terms of losses (prevention framed)
Number of subjects: 0
Study 9491583 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion-framed task incentives
Number of subjects: 0
Study 9491583 — intervention group
Group type: COMPARATOR
Intervention: Prevention-framed task incentives
Number of subjects: 0
Study 8737557 — intervention group
Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 70
Study 8737557 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy with topical beta blockers
Number of subjects: 70
Study 3595257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (M) mixed with poly(I).poly(C) (90 mg/m2)
Number of subjects: 5
Study 3595257 — intervention group
Group type: COMPARATOR
Intervention: Free Mitoxantrone (M) (30 mg/m2)
Number of subjects: 5
Study 29936289 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarmist video
Number of subjects: 44
Study 29936289 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 44
Study 29936289 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-ON trial
Number of subjects: 44
Study 29936289 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-OFF trial
Number of subjects: 44
Study 27809792 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIDs withdrawal
Number of subjects: 612
Study 27809792 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 612
Study 25068178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural adaptation of a social cognitive theory‐based HIV behavioral prevention program
Number of subjects: 0
Study 22717330 — intervention group
Group type: EXPERIMENTAL
Intervention: rHA 45 μg with Advax™ adjuvant
Number of subjects: 281
Study 22717330 — intervention group
Group type: COMPARATOR
Intervention: rHA alone
Number of subjects: 281
Study 22717330 — intervention group
Group type: EXPERIMENTAL
Intervention: rHA 3, 11 or 45 μg with or without adjuvant
Number of subjects: 281
Study 19535612 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship-based HIV/STI prevention intervention
Number of subjects: 264
Study 18795960 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine) 800 mg bid
Number of subjects: 116
Study 18795960 — intervention group
Group type: COMPARATOR
Intervention: Control PI
Number of subjects: 116
Study 18795960 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125
Number of subjects: 116
Study 15657693 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (prednisolone acetate 1% eye drops 5x/day for 6 months)
Number of subjects: 40
Study 15657693 — intervention group
Group type: COMPARATOR
Intervention: Combined systemic (fluocortolone 1 mg/kg body weight per day tapered within 3 weeks) and topical steroids
Number of subjects: 40
Study 12629101 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg T enanthate, im, weekly plus 125 micro g LNG, orally, daily (T+LNG)
Number of subjects: 100
Study 12629101 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone alone (T)
Number of subjects: 100
Study 12629101 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel alone (LNG)
Number of subjects: 100
Study 12629101 — intervention group
Group type: COMPARATOR
Intervention: Placebo T plus placebo LNG (placebo)
Number of subjects: 100
Study 12629101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of T+LNG
Number of subjects: 100
Study 11279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine 4%
Number of subjects: 131
Study 11279969 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo 0.5 mL
Number of subjects: 131
Study 9057446 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent malaria patients with more than five attacks
Number of subjects: 61
Study 9057446 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent malaria patients
Number of subjects: 61
Study 9057446 — intervention group
Group type: COMPARATOR
Intervention: Fresh and recurrent malaria patients
Number of subjects: 61
Study 1907362 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate (0.12 mg/kg)
Number of subjects: 6
Study 1907362 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G: 0.03 mg/kg)
Number of subjects: 6
Study 1907362 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G: 0.06 mg/kg)
Number of subjects: 6
Study 1907362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6351658 — intervention group
Group type: COMPARATOR
Intervention: Group A (prednisone and vincristine)
Number of subjects: 30
Study 6351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (prednisone, vincristine, and L-asparaginase)
Number of subjects: 30
Study 31350296 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early and more frequent mobilization in addition to usual care
Number of subjects: 56
Study 31350296 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study 29587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise (STRUC)
Number of subjects: 480
Study 29587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Free/unstructured gym use (FREE)
Number of subjects: 480
Study 29587703 — intervention group
Group type: COMPARATOR
Intervention: Measurement only comparator (CONT)
Number of subjects: 480
Study 29587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional supervised exercise (STRUC)
Number of subjects: 480
Study 29587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (COMB)
Number of subjects: 480
Study 29587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counselling (PAC)
Number of subjects: 480
Study 29587703 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparator (CONT)
Number of subjects: 480
Study 27243774 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP
Number of subjects: 399
Study 27243774 — intervention group
Group type: COMPARATOR
Intervention: 9H
Number of subjects: 399
Study 24485633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose furosemide (HDF, n=50, 20mg/h)
Number of subjects: 161
Study 24485633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose furosemide and low-dose dopamine (LDFD, n=56, 5mg/h and 5 μg kg(‐1)min(‐1))
Number of subjects: 161
Study 24485633 — intervention group
Group type: COMPARATOR
Intervention: Low-dose furosemide (LDF, n=55, 5mg/h)
Number of subjects: 161
Study 22143923 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline (42°C, 107°F)
Number of subjects: 462
Study 22143923 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature saline
Number of subjects: 462
Study 20426780 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL PDT with visible light and water-filtered infrared A (VIS+wIRA)
Number of subjects: 80
Study 20426780 — intervention group
Group type: COMPARATOR
Intervention: MAL PDT with light from light-emitting diodes (LEDs)
Number of subjects: 80
Study 18034900 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews (CATI)
Number of subjects: 823
Study 18034900 — intervention group
Group type: COMPARATOR
Intervention: Self-administered questionnaires
Number of subjects: 823
Study 18034900 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of administration (telephone interview first)
Number of subjects: 823
Study 16136843 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training program (N = 24) consisting of four sessions, including watching investigators administer the Texas Functional Living Scale and cueing patients to perform tasks.
Number of subjects: 47
Study 16136843 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (N = 23)
Number of subjects: 47
Study 12586806 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atrasentan
Number of subjects: 288
Study 12586806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 10509757 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g of cooked Brussels sprouts per day
Number of subjects: 10
Study 10509757 — intervention group
Group type: COMPARATOR
Intervention: Glucosinolate-free diet
Number of subjects: 10
Study 7860905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 100
Study 7860905 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100
Study 7860905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and atenolol
Number of subjects: 100
Study 1753042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at 1 minute after standing
Number of subjects: 4736